<DOC>
	<DOCNO>NCT00679341</DOCNO>
	<brief_summary>This Phase II , randomize , multicenter , international , 2-arm , open-label clinical trial design explore efficacy safety trastuzumab emtansine ( T-DM1 ) relative combination trastuzumab docetaxel patient human epidermal growth factor receptor 2 ( HER2 ) -positive , unresectable , locally advanced breast cancer and/or metastatic breast cancer receive prior chemotherapy metastatic disease .</brief_summary>
	<brief_title>A Study Efficacy Safety Trastuzumab Emtansine ( Trastuzumab-MCC-DM1 ) vs. Trastuzumab ( Herceptin® ) Docetaxel ( Taxotere® ) Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy Metastatic Disease</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma breast locally advance metastatic disease , candidate chemotherapy . Human epidermal growth factor receptor 2 ( HER2 ) positive . No prior chemotherapy metastatic breast cancer ( MBC ) . Measurable disease . Age ≥ 18 year . For woman childbearing potential men partner childbearing potential , agreement use highly effective , nonhormonal form contraception 2 effective form nonhormonal contraception patient and/or partner . Contraception use must continue duration study treatment least 6 month last dose study treatment . Male patient whose partner pregnant use condom duration study . History chemotherapy MBC . An interval &lt; 6 month completion cytotoxic chemotherapy neoadjuvant adjuvant setting time metastatic diagnosis . Trastuzumab ≤ 21 day prior randomization . Hormone therapy &lt; 7 day prior randomization . Current peripheral neuropathy Grade ≥ 3 . History malignancy within last 5 year , except appropriately treat carcinoma situ cervix , nonmelanoma skin carcinoma , Stage I uterine cancer , cancer similar outcome previously mention . Previous radiotherapy treatment unresectable , locally advanced metastatic breast cancer allow 25 % marrowbearing bone irradiate last fraction radiotherapy administer within approximately 3 week prior randomization . Brain metastasis untreated , symptomatic , require therapy control symptom radiation , surgery , therapy control symptom brain metastasis within 2 month prior randomization . History exposure follow cumulative dos anthracyclines : Doxorubicin liposomal doxorubicin &gt; 500 mg/m^2 ; epirubicin &gt; 900 mg/m^2 ; mitoxantrone &gt; 120mg/m^2 idarubicin &gt; 90 mg/m^2 . Current unstable angina . History symptomatic congestive heart failure , ventricular arrhythmia require treatment . History myocardial infarction within 6 month prior randomization . Left ventricular ejection fraction ( LVEF ) 50 % within approximately 28 day prior randomization . History decrease LVEF symptomatic congestive heart failure ( CHF ) previous adjuvant trastuzumab treatment . Cardiac troponin I ≥ 0.2 ng/mL within 28 day randomization . Severe dyspnea rest complication advance malignancy require current continuous oxygen therapy . Current severe , uncontrolled systemic disease ( eg , clinically significant cardiovascular , pulmonary , metabolic disease ; wound heal disorder ; ulcer ; bone fracture ) . Major surgical procedure significant traumatic injury within approximately 28 day prior randomization anticipation need major surgery course study treatment . Current pregnancy lactation . History receive investigational treatment within approximately 28 day prior randomization . Current known infection human immunodeficiency virus ( HIV ) , active hepatitis B and/or hepatitis C virus . History intolerance ( include Grade 34 infusion reaction ) hypersensitivity trastuzumab , murine protein , docetaxel . Known hypersensitivity study drug , include excipients , drug formulate polysorbate 80 . Assessed investigator unable unwilling comply requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>HER2-positive breast cancer</keyword>
	<keyword>HER2</keyword>
	<keyword>Herceptin</keyword>
	<keyword>Taxotere</keyword>
	<keyword>MBC</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>TDM1</keyword>
	<keyword>TDM-1</keyword>
	<keyword>HER2-positive</keyword>
	<keyword>HER2+</keyword>
	<keyword>HER2 positive breast cancer</keyword>
	<keyword>HER2+ breast cancer</keyword>
	<keyword>Armed Herceptin</keyword>
	<keyword>Trastuzumab emtansine</keyword>
	<keyword>Trastuzumab DM1</keyword>
</DOC>